文献速递MDS 与骨髓增殖性肿瘤白血病

人工智能骨髓增生异常综合征预后评分系统在慢性粒单核细胞白血病中的验证:一种改进风险分层的新方法

Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
PubMed 文献 · Br J Haematol · 2024-02-27

本研究利用西班牙登记处1343例和台湾医院75例数据,验证人工智能骨髓增生异常综合征预后评分系统(AIPSS-MDS)在慢性粒单核细胞白血病中的表现。西班牙队列中AIPSS-MDS准确预测总生存和无白血病生存,优于修订版IPSS;台湾队列中同样准确,优于IPSS,并在区分患者结局方面优于CPSS和分子CPSS。两个队列表现一致,显示其可推广性。

要点

  • 西班牙队列中AIPSS-MDS准确预测总生存和无白血病生存,优于修订版IPSS。
  • 台湾队列中AIPSS-MDS准确预测总生存和无白血病生存,优于IPSS、CPSS和分子CPSS。
  • 两个队列表现一致,显示AIPSS-MDS在CMML中具有可推广性。

核心结论

  • AIPSS-MDS在西班牙和台湾两个队列中均能准确预测CMML患者的总生存和无白血病生存,表现优于传统评分系统,具有可推广性。

研究设计与样本

  • 研究利用西班牙登记处1343例和台湾医院75例CMML患者数据,验证AIPSS-MDS并与传统评分系统比较性能。

主要发现

  • 西班牙队列中AIPSS-MDS准确预测总生存和无白血病生存,优于修订版IPSS。
  • 台湾队列中AIPSS-MDS准确预测总生存和无白血病生存,优于IPSS,并在区分患者结局方面优于CPSS和分子CPSS。
  • AIPSS-MDS在两个队列中表现一致,显示其可推广性。

关键数值与推荐

  • 西班牙登记处纳入1343例CMML患者。
  • 台湾医院纳入75例CMML患者。

临床怎么用

  • 作者认为AIPSS-MDS可作为CMML个性化治疗决策的有价值工具,帮助临床医生识别可能从不同治疗干预中获益的高风险患者。

局限性

  • 未来研究应探索将遗传信息整合到AIPSS-MDS中,以进一步完善CMML风险分层并改善患者结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic myelomonocytic leukaemia (CMML) is a rare haematological disorder characterized by monocytosis and dysplastic changes in myeloid cell lineages. Accurate risk stratification is essential for guiding treatment decisions and assessing prognosis. This study aimed to validate the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes (AIPSS-MDS) in CMML and to assess its performance compared with traditional scores using data from a Spanish registry (n = 1343) and a Taiwanese hospital (n = 75). In the Spanish cohort, the AIPSS-MDS accurately predicted overall survival (OS) and leukaemia-free survival (LFS), outperforming the Revised-IPSS score. Similarly, in the Taiwanese cohort, the AIPSS-MDS demonstrated accurate predictions for OS and LFS, showing superiority over the IPSS score and performing better than the CPSS and molecular CPSS scores in differentiating patient outcomes. The consistent performance of the AIPSS-MDS across both cohorts highlights its generalizability. Its adoption as a valuable tool for personalized treatment decision-making in CMML enables clinicians to identify high-risk patients who may benefit from different therapeutic interventions. Future studies should explore the integration of genetic information into the AIPSS-MDS to further refine risk stratification in CMML and improve patient outcomes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mosquera Orgueira A, Perez Encinas MM, Diaz Varela N, et al. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification. Br J Haematol. 2024. PMID: 38411250. doi:10.1111/bjh.19341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。